← Eichor
Study identifier: NCT05755672 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

On-treatment Biomarkers in Metastatic Colorectal Cancer for Life

Condition: Metastatic Colorectal Cancer · Chemotherapy Effect · Peritoneal Metastases  ·  Sponsor: Region Skane

PhaseN/A
Planned participants100
Who can joinAll sexes, 18 Years to 110 Years
Healthy volunteersNo

About this study

By virtue of an increased strategic use of cytotoxic and biological agents, and more options for locoregional treatment, the survival of patients with metastatic colorectal cancer (mCRC) has improved considerably in the past decades. The personalized approach to systemic treatment is further aided by the use of complementary molecular biomarkers. However, the evolutionary dynamics of mCRC, a disease harnessed by multiple adaptive genetic alterations towards its final stages, poses a particular challenge to single-sample biomarker analyses and standardized linear treatment protocols. The aim of the On-treatment biomarkers in metastatic ColorectAL cancer for Life (On-CALL) study is to generate further knowledge on the evolutionary progression of mCRC during treatment, and to elucidate the mechanisms underlying the therapeutic failure still seen in a substantial number of patients. The On-CALL study is a prospective, single-arm observational study. All patients diagnosed with synchronous mCRC treated with curative intent at Skåne University Hospital will be invited to participate. Clinical and histopathological data will be compiled at study entry. An individual tissue microarray block with samples from resected primary tumours and metastases representing the full extent of the tumour spread will be constructed for each patient. Blood samples will be drawn for biomarker analyses at multiple time points prior to, during and after systemic treatment. DNA sequencing of tumour tiss…

This description comes directly from the study's public registry record.

Talk to the study team

Danyil Kuznyecov, M.D.  ·  +46 725972072  ·  danyil_szergejevics.kuznyecov@med.lu.se

Christina Siesing, M.D. PhD.  ·  +4646177841  ·  christina.siesing@med.lu.se

Always discuss trial participation with your own doctor first.

Locations (2)

Department of Oncology, Hematology and Radiophysics, Skane University HospitalLund, Skåne County, SwedenRecruiting
Department of Oncology, Hematology and Radiophysics, Skane University HospitalMalmö, Skåne County, SwedenRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05755672